FDA supplemental approval: Oxycodone AND Acetaminophen (REMS)

AI Summary

The FDA granted supplemental approval on 18 June 2026 for three oral tablet formulations of oxycodone and acetaminophen (5 mg, 7.5 mg, and 10 mg oxycodone HCl each combined with 325 mg acetaminophen) under a Risk Evaluation and Mitigation Strategy (REMS). This is a regulatory action that confirms manufacturing and labelling compliance; it does not report clinical trial results, efficacy data, or comparative benefit.

Plain-language summary

FDA supplemental approval action for oxycodone/acetaminophen REMS; describes regulatory authority action only, not clinical evidence or efficacy.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This record confirms FDA regulatory approval of specific formulations under a REMS framework; it does not provide clinical trial data, safety outcomes, efficacy comparisons, or guidance on clinical use. Practitioners should consult the approved product labelling and prescribing information for therapeutic details.

Caveats

• Record contains no clinical trial results, efficacy data, or comparative safety information
• REMS approval status does not imply new clinical evidence; reflects risk management and labelling compliance
• No population studied, no sample size, and no clinical outcomes reported
• This is a regulatory action only; refer to the approved package insert for clinical information

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.